Sign in

    Racheal Vatnsdal

    Research Analyst at JPMorgan

    Racheal Vatnsdal is an Executive Director of Equity Research at JPMorgan Chase, specializing in healthcare sector coverage and based in New York City. She covers companies such as Henry Schein, Adaptive Biotechnologies, Avantor, 10x Genomics, Twist Bioscience, and Caris Life Sciences, delivering analyst ratings whose best-performing call, CareDx Inc., generated a return of +194.4% over a one-year period. Having started at JPMorgan after serving as Senior Healthcare Analyst elsewhere, Vatnsdal has amassed over 250 stock ratings with a 41% success rate and an average return per rating of -0.1%. She holds professional credentials in equity research and securities analysis, with responsibilities reflecting licensing and regulatory compliance typical for senior analysts in her role.

    Racheal Vatnsdal's questions to AKYA leadership

    Racheal Vatnsdal's questions to AKYA leadership • Q1 2024

    Question

    Asked for more detail on the academic market, including budget assumptions in guidance, and inquired about performance by geographic region, specifically the contribution from China.

    Answer

    The company's guidance assumes flat NIH and EU Horizon budgets. Geographically, APAC was the most challenged region in Q1, representing about 18% of total revenue, with China making up 60-70% of that APAC revenue. North America and EMEA saw similar low-to-high single-digit year-over-year challenges.

    Ask Fintool Equity Research AI